Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INMB
INMB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INMB News
INmune Bio Reveals New Data on Alzheimer's Treatment
10h ago
Newsfilter
INmune Bio Submits CORDStrom Patent Application to USPTO
Jul 01 2026
Yahoo Finance
GT Biopharma Advances NK Cell Immunotherapy with TriKE Candidates
May 19 2026
Newsfilter
INmune Bio Receives FDA Fast Track Designation for XPro™ in Alzheimer's Treatment
May 14 2026
Newsfilter
INmune Bio Reports Q1 2026 Earnings Beat Expectations
May 07 2026
seekingalpha
INmune Bio Reports $45.9M Loss in 2025 Earnings
Mar 31 2026
Yahoo Finance
INmune Bio Reports Disappointing FY Results
Mar 30 2026
seekingalpha
INmune Bio Reports Financial Results for FY 2025
Mar 30 2026
Yahoo Finance
INmune Bio to Announce FY Earnings on March 30
Mar 29 2026
seekingalpha
INmune Bio Hosts Webinar on Alzheimer's Treatment Pathway
Feb 23 2026
Newsfilter
INmune Bio to Host CORDStrom Webinar on RDEB Treatment
Feb 19 2026
Newsfilter
INmune Bio Receives FDA Support for Alzheimer’s Therapy
Feb 12 2026
stocktwits
INmune Bio Publishes Overview on Future Applications of MSC Therapies
Dec 05 2025
Globenewswire
INmune Bio Presents New XPro1595 Data for Alzheimer's Disease at CTAD
Dec 01 2025
Globenewswire
INmune Bio Successfully Completes Initial Commercial Pilot-Scale Production of CORDStrom™ at CGT Catapult
Sep 15 2025
Newsfilter
INmune Bio (INMB) Declines 23.8% Over the Past Month, But a Trend Reversal Could Be Imminent
Sep 08 2025
NASDAQ.COM
Show More News
